Search Results - jessica+hong

4 Results

Sort By:

High Affinity Cross Species Single Domain Antibodies Targeting Mesothelin

Abstract: Mesothelin is a cell surface protein that is an excellent target for immunotherapy because of its limited expression on normal tissues and its high expression on many cancers, including mesothelioma, cholangiocarcinoma, pancreatic, ovarian, lung, stomach, bile duct, and triple-negative breast cancer. Researchers at the National Cancer Institute’s...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Ira Pastan, Jessica Hong, Nan Li

Keywords(s): ADC, Antibody-drug Conjugate, Bispecific Antibody, CAR, chimeric antigen receptor, HO, MESOTHELIN, Mesothelioma, Recombinant Immunotoxins, RITs

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Application > Therapeutics

IgG4 Hinge Containing Chimeric Antigen Receptors Targeting Glypican-1 For Treating Solid Tumors

Abstract: Pancreatic cancer is the fourth most common cause of cancer deaths in the U.S. The overall 5-year survival rate is 8.5%. Glypican-1 (GPC1) is a cell surface heparan sulfate proteoglycan protein overexpressed in pancreatic cancer. Due to preferential expression, GPC1 represents a potential candidate for targeted therapy for pancreatic cancer...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Jessica Hong

Keywords(s): cancer therapeutic, CAR, chimeric antigen receptor, Glypican-1, GPC-1, Hinge, HO, IgG4, Immunoglobulin subclass 4, NANOBODY, Pancreatic Cancer, Single Domain Antibody

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, Collaboration Sought > Licensing, TherapeuticArea > Oncology

Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron

Abstract: Since its emergence in 2019, COVID-19 infected over 600 million people and over 6 million people have died from the disease. COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Neutralizing antibodies have been developed to bind to the receptor binding domain (RBD) on the spike (S) protein. Blocking the interaction of the RBD...

Published: 7/29/2024 | Inventor(s): Mitchell Ho, Jessica Hong, Jesse Buffington, Zhijian Duan

Keywords(s): ANTIBODY, Camel Nanobody, CORONAVIRUS, COVID-19, HO, Infectious Diseases, Nanobodies, Pandemic, SARS-CoV-2, therapeutic, Vaccine

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease, Application > Therapeutics, Collaboration Sought > Licensing

Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19

Abstract: The COVID-19 pandemic is a worldwide public health crisis with over 100 million confirmed cases and 2.4 million deaths as of February 2021. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. SARS-COV-2 infects hosts via its spike (S) protein. The S protein contains the receptor binding domain (RBD) that binds to the angiotensin converting...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Jessica Hong

Keywords(s): ANTIBODY, antigen-binding fragment, CORONAVIRUS, COVID-19, HO, NANOBODY, respiratory INFECTION, S Protein, SARS-CoV-2, spike protein

Category(s): TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics